Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2024-08-05 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
简式权益变动报告书（国新投资有限公司）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of 国新投资有限公司 in 天士力医药集团股份有限公司, including the number of shares acquired, the method of acquisition (agreement transfer), the price, payment terms, and related legal and procedural disclosures. The document includes detailed information about the shareholder, the transaction, and compliance with relevant securities laws and regulations. There is no indication that this is an annual report, earnings release, or any other financial report. Instead, it is a formal notification of a change in major shareholding. According to the filing definitions, notifications of changes in significant share ownership levels (crossing thresholds) fall under the category "Major Shareholding Notification" (Code: MRQ). The document length and detail confirm it is the report itself, not just an announcement of a report. Therefore, the correct classification is MRQ with high confidence.
2024-08-05 Chinese
天士力关于T89预防及治疗急性高原反应适应症美国FDA临床试验进展暨风险提示公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about the progress and risk update of a clinical trial (FDA Phase III) for a drug (T89) for prevention and treatment of acute mountain sickness. It discusses clinical trial progress, FDA meetings, and future plans. The document is relatively short (2138 characters) and primarily serves as a regulatory update or announcement rather than a full clinical or financial report. It does not contain financial statements, detailed financial analysis, or comprehensive management discussion. It is not a report of voting results, board changes, or legal proceedings. It is a regulatory announcement about clinical trial progress and risk disclosure, fitting best under Regulatory Filings (RNS).
2024-08-04 Chinese
天士力关于控股股东及其一致行动人签署《股份转让协议》暨控制权变更的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a significant equity transfer involving the controlling shareholder of a company, TianShiLi Pharmaceutical Group Co., Ltd. It describes the transfer of shares from the current controlling shareholder and its concerted parties to another company, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., including shareholding percentages, transaction prices, payment terms, and governance changes. The document also discusses the impact on control and the subsequent changes in actual control of the company. It includes detailed information about the parties involved, the agreements signed, and the regulatory approvals required. This is a classic example of a Capital/Financing Update (CAP) filing, as it concerns a major shareholding transfer and control change, but it is not a full annual or interim report, nor a proxy or voting announcement. It is not a merger filing (MA) or takeover bid (TAR) but a share transfer and control change announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2024-08-04 Chinese
天士力关于控股股东筹划控制权变更事项的复牌公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the resumption of trading (复牌公告) of the company's stock following a suspension due to the controlling shareholder planning a change in control. It references regulatory rules about suspension and resumption of trading and provides dates for suspension and resumption. The document does not contain financial statements, detailed financial data, or management discussion. It is a regulatory announcement about stock trading status related to a control change event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-08-04 Chinese
天士力关于控股股东筹划控制权变更事项的停牌公告
Regulatory Filings Classification · 95% confidence The document is a notice about the suspension of trading (停牌公告) due to the controlling shareholder planning a change in control through share transfer. It mentions the stock code, suspension start date, and regulatory compliance with stock exchange rules. The document is short (860 characters) and serves as an announcement of a trading halt related to a potential control change, not a detailed report or financial statement. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about trading status and control change planning, not a full report or detailed capital/financing update.
2024-07-31 Chinese
天士力关于员工持股计划展期的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the extension of the duration of two employee stock ownership plans. It details the board meeting dates, voting results, and the decision to extend the plans by 12 months. The document does not contain financial statements, audit information, or detailed financial analysis. It is a formal announcement about a corporate governance action related to employee stock plans, which fits best under a regulatory announcement category rather than a full report or financial filing. Given the nature and length of the document, it is not a full report but an announcement of a corporate action. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-07-19 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.